CDX-014 is a fully human monoclonal antibody-drug conjugate (ADC) that targets T-cell immunoglobulin mucin-1 (TIM-1). TIM-1 expression is upregulated in several cancers, most notably renal cell and ovarian carcinomas, and has very restricted expression in healthy tissue. The TIM-1-targeting antibody, CR014, is linked to a potent cytotoxic, monomethyl auristatin E (MMAE), using Seattle Genetics' proprietary technology. CDX-014 is designed to be stable in the bloodstream, but to release MMAE upon internalization into TIM-1-expressing tumor cells, resulting in a targeted cell-killing effect.

Ongoing Clinical Trials

CDX-014 is in development for the treatment of advanced/metastatic clear cell or papillary renal cell carcinoma, and a Phase 1 dose-escalation study is currently open to enrollment.

For more information on the CDX-014 program, view recent scientific presentations and publications.